Rate My Professor Maria Ascierto

In addition to her professorial role, Professor Ascierto serves as Head of the Scotland CRUK Clinical Biomarkers Hub, contributing significantly to precision oncology. She has obtained major grants, including one from the Beatson Cancer Charity for 2025-2027 titled 'Unleash Immune-Monitoring in Patients with Solid Tumours using Cytek Spectral Cytometry' and another from NHS Greater Glasgow and Clyde Endowment Funds for 2024-2027 titled 'Unchaining spatial omics and immune monitoring in clinical practice through LUNAPHORE technology: Implications for Precision Immunotherapy.' Notable publications include 'Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors' (Journal for ImmunoTherapy of Cancer, 2024), 'Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases' (npj Precision Oncology, 2023), 'Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer' (Cancer Discovery, 2021), 'Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy' (Clinical Cancer Research, 2017), 'The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma' (Cancer Immunology Research, 2016), and 'Oncogenic signalling pathways in cancer immunotherapy: leader or follower in this delicate dance?' (International Journal of Molecular Sciences, 2025). Prior to Glasgow, she held a postdoctoral fellowship at Johns Hopkins Medicine. She is an editorial board member for Precision Oncology.